Serotonin control of sleep-wake behavior.

Based on electrophysiological, neurochemical, genetic and neuropharmacological approaches, it is currently accepted that serotonin (5-HT) functions predominantly to promote wakefulness (W) and to inhibit REM (rapid eye movement) sleep (REMS). Yet, under certain circumstances the neurotransmitter contributes to the increase in sleep propensity. Most of the serotonergic innervation of the cerebral cortex, amygdala, basal forebrain (BFB), thalamus, preoptic and hypothalamic areas, raphe nuclei, locus coeruleus and pontine reticular formation comes from the dorsal raphe nucleus (DRN). The 5-HT receptors can be classified into at least seven classes, designated 5-HT(1-7). The 5-HT(1A) and 5-HT(1B) receptor subtypes are linked to the inhibition of adenylate cyclase, and their activation evokes a membrane hyperpolarization. The actions of the 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptor subtypes are mediated by the activation of phospholipase C, with a resulting depolarization of the host cell. The 5-HT(3) receptor directly activates a 5-HT-gated cation channel which leads to the depolarization of monoaminergic, aminoacidergic and cholinergic cells. The primary signal transduction pathway of 5-HT(6) and 5-HT(7) receptors is the stimulation of adenylate cyclase which results in the depolarization of the follower neurons. Mutant mice that do not express 5-HT(1A) or 5-HT(1B) receptor exhibit greater amounts of REMS than their wild-type counterparts, which could be related to the absence of a postsynaptic inhibitory effect on REM-on neurons of the laterodorsal and pedunculopontine tegmental nuclei (LDT/PPT). 5-HT(2A) and 5-HT(2C) receptor knock-out mice show a significant increase of W and a reduction of slow wave sleep (SWS) which has been ascribed to the increase of catecholaminergic neurotransmission involving mainly the noradrenergic and dopaminergic systems. Sleep variables have been characterized, in addition, in 5-HT(7) receptor knock-out mice; the mutants spend less time in REMS that their wild-type counterparts. Direct infusion of the 5-HT(1A) receptor agonists 8-OH-DPAT and flesinoxan into the DRN significantly enhances REMS in the rat. In contrast, microinjection of the 5-HT(1B) (CP-94253), 5-HT(2A/2C) (DOI), 5-HT(3) (m-chlorophenylbiguanide) and 5-HT(7) (LP-44) receptor agonists into the DRN induces a significant reduction of REMS. Systemic injection of full agonists at postsynaptic 5-HT(1A) (8-OH-DPAT, flesinoxan), 5-HT(1B) (CGS 12066B, CP-94235), 5-HT(2C) (RO 60-0175), 5-HT(2A/2C) (DOI, DOM), 5-HT(3) (m-chlorophenylbiguanide) and 5-HT(7) (LP-211) receptors increases W and reduces SWS and REMS. Of note, systemic administration of the 5-HT(2A/2C) receptor antagonists ritanserin, ketanserin, ICI-170,809 or sertindole at the beginning of the light period has been shown to induce a significant increase of SWS and a reduction of REMS in the rat. Wakefulness was also diminished in most of these studies. Similar effects have been described following the injection of the selective 5-HT(2A) receptor antagonists volinanserin and pruvanserin and of the 5-HT(2A) receptor inverse agonist nelotanserin in rodents. In addition, the effects of these compounds have been studied on the sleep electroencephalogram of subjects with normal sleep. Their administration was followed by an increase of SWS and, in most instances, a reduction of REMS. The administration of ritanserin to poor sleepers, patients with chronic primary insomnia and psychiatric patients with a generalized anxiety disorder or a mood disorder caused a significant increase in SWS. The 5-HT(2A) receptor inverse agonist APD-125 induced also an increase of SWS in patients with chronic primary insomnia. It is known that during the administration of benzodiazepine (BZD) hypnotics to patients with insomnia there is a further reduction of SWS and REMS, whereas both variables tend to remain decreased during the use of non-BZD derivatives (zolpidem, zopiclone, eszopiclone, zaleplon). Thus, the association of 5-HT(2A) antagonists or 5-HT(2A) inverse agonists with BZD and non-BZD hypnotics could be a valid alternative to normalize SWS in patients with primary or comorbid insomnia.

[1]  T. Blackburn,et al.  Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS , 2000, Neuropharmacology.

[2]  R. Luthringer,et al.  Effects of Antidepressant Drugs on Sleep EEG in Patients with Major Depression , 1999 .

[3]  S. Maier,et al.  Differential Expression of 5 HT-1 A , α 1 b Adrenergic , CRF-R 1 , and CRF-R 2 Receptor mRNA in Serotonergic , γ-Aminobutyric Acidergic , and Catecholaminergic Cells of the Rat Dorsal Raphe Nucleus , 2008 .

[4]  L. Descarries,et al.  Cellular and subcellular distribution of the serotonin 5‐HT2A receptor in the central nervous system of adult rat , 1999, The Journal of comparative neurology.

[5]  D. Rasmusson,et al.  The role of basal forebrain neurons in tonic and phasic activation of the cerebral cortex , 1999, Progress in Neurobiology.

[6]  T. Roth,et al.  APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia. , 2008, Sleep.

[7]  Paul J. Harrison,et al.  The distribution of 5-HT(6) receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]SB-258585. , 2002, Brain research.

[8]  J. Parnavelas.  Neurotransmitters in the cerebral cortex. , 1990, Progress in brain research.

[9]  S. Stahl,et al.  Inhibition of REM sleep by ipsapirone, A 5HT1A agonist, in normal volunteers , 1994, Psychopharmacology.

[10]  Increased GABAergic activity in the region of the pedunculopontine and deep mesencephalic reticular nuclei reduces REM sleep and impairs learning in rats. , 2010, Behavioral neuroscience.

[11]  M. Sheard,et al.  The effect of p-chlorophenylalanine on behavior in rats: relation to brain serotonin and 5-hydroxyindoleacetic acid. , 1969, Brain research.

[12]  M. Hamon,et al.  Quantitative autoradiographic mapping of 5‐HT3 receptors in the rat CNS using [125I]iodo‐zacopride and [3H]zacopride as radioligands , 1992, Synapse.

[13]  S. Nair,et al.  Activation of 5‐HT2 receptors enhances the release of acetylcholine in the prefrontal cortex and hippocampus of the rat , 2004, Synapse.

[14]  A. Sleight,et al.  5-HT 2 C Receptor Agonists : Pharmacological Characteristics and Therapeutic Potential , 1998 .

[15]  J. Monti,et al.  Effects of the serotonin 5-HT2A/2C receptor agonist DOI and of the selective 5-HT2A or 5-HT2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat. , 2006, European journal of pharmacology.

[16]  S. S. Tenen,et al.  The effects of p-chlorophenylalanine, a serotonin depletor, on avoidance acquisition, pain sensitivity and related behavior in the rat , 2004, Psychopharmacologia.

[17]  T. Sharp,et al.  Neurochemical and anatomical identification of fast- and slow-firing neurones in the rat dorsal raphe nucleus using juxtacellular labelling methods in vivo , 2003, Neuroscience.

[18]  L. Levita,et al.  Bi-directional modulation of bed nucleus of stria terminalis neurons by 5-HT: molecular expression and functional properties of excitatory 5-HT receptor subtypes , 2009, Neuroscience.

[19]  D. Kupfer,et al.  Effects of para-chlorophenylalanine on sleep in man. , 1969, Electroencephalography and Clinical Neurophysiology.

[20]  R. A. Lovell,et al.  THE EFFECT OF PARACHLOROPHENYLALANINE ON SLEEP IN THE RAT: SOME IMPLICATIONS FOR THE SEROTONIN-SLEEP HYPOTHESIS , 1973 .

[21]  T. Branchek,et al.  A receptor autoradiographic and in situ hybridization analysis of the distribution of the 5‐ht7 receptor in rat brain , 1996, British journal of pharmacology.

[22]  J. Monti,et al.  Effects on Sleep of Melanin-Concentrating Hormone (MCH) Microinjections into the Dorsal Raphe Nucleus of the Cat , 2009, Sleep and Vigilance.

[23]  J. Monti,et al.  The effects of selective activation of the 5-HT3 receptor with m-chlorophenylbiguanide on sleep and wakefulness in the rat. , 1993, European journal of pharmacology.

[24]  G. Gessa,et al.  Compulsive Sexual Activity Induced by p-Chlorophenylalanine in Normal and Pinealectomized Male Rats , 1969, Science.

[25]  R. Silveira,et al.  Effects of accumbens m-chlorophenylbiguanide microinjections on sleep and waking in intact and 6-hydroxydopamine-treated rats. , 1999, European journal of pharmacology.

[26]  R. Stickgold,et al.  The neuropsychology of REM sleep dreaming. , 1998, Neuroreport.

[27]  R. Hen,et al.  Involvement of 5-HT1A Receptors in Homeostatic and Stress-Induced Adaptive Regulations of Paradoxical Sleep: Studies in 5-HT1A Knock-Out Mice , 2002, The Journal of Neuroscience.

[28]  C. Marsden,et al.  5-ht6 receptors. , 2004, Current drug targets. CNS and neurological disorders.

[29]  M. Jouvet,et al.  Insomnia following parachlorophenylalanine in the rat. , 1968, European journal of pharmacology.

[30]  M. Opp,et al.  Antagonism of corticotropin-releasing hormone alters serotonergic-induced changes in brain temperature, but not sleep, of rats. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[31]  Joseph P. Huston,et al.  Physiological and behavioral effects of parachlorophenylalanine in the rat , 1973, Psychopharmacologia.

[32]  W. Dement,et al.  Buspirone: An anxiolytic without sedative effect , 2004, Psychopharmacology.

[33]  A. Alonso,et al.  Pharmacological and Immunohistochemical Evidence for Serotonergic Modulation of Cholinergic Nucleus Basalis Neurons , 1993, The European journal of neuroscience.

[34]  A. Coenen,et al.  Effects of sertindole on sleep-wake states, electroencephalogram, behavioral patterns, and epileptic activity of rats , 1995, Pharmacology Biochemistry and Behavior.

[35]  I. Oswald,et al.  Effects of repeated ritanserin on middle-aged poor sleepers , 2004, Psychopharmacology.

[36]  J. Monti,et al.  Activation of serotonin 5-HT1B receptor in the dorsal raphe nucleus affects REM sleep in the rat , 2010, Behavioural Brain Research.

[37]  J. Schwartz,et al.  A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. , 1993, Biochemical and biophysical research communications.

[38]  J. Leysen,et al.  Functional role of 5-HT2 receptors in the regulation of sleep and wakefulness in the rat , 2004, Psychopharmacology.

[39]  M. Radulovački,et al.  Slow Wave Sleep: Physiological, Pathophysiological and Functional Aspects , 1989 .

[40]  J. Monti,et al.  Effects of the 5-HT6 receptor antagonists SB-399885 and RO-4368554 and of the 5-HT2A receptor antagonist EMD 281014 on sleep and wakefulness in the rat during both phases of the light–dark cycle , 2011, Behavioural Brain Research.

[41]  F. Reinoso-suárez,et al.  Brain structures and mechanisms involved in the generation of REM sleep. , 2001, Sleep medicine reviews.

[42]  J. Monti,et al.  5-HT receptor agonists 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and 8-OH-DPAT increase wakefulness in the rat , 1990 .

[43]  P. Cowen,et al.  Slow wave sleep in humans: Role of 5-HT2A and 5-HT2C receptors , 1994, Neuropharmacology.

[44]  Dennis S. Charney,et al.  Neuropsychopharmacology : The Fifth Generation of Progress , 2002 .

[45]  J. Adrien.  Sleep and waking in mutant mice that do not express various proteins involved in serotonergic neurotransmission such as the serotonergic transporter, monoamine oxidase A, and 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C and 5-HT7 receptors , 2008 .

[46]  Manfred Göthert,et al.  5-HT Receptor Regulation of Neurotransmitter Release , 2007, Pharmacological Reviews.

[47]  S. Haj-Dahmane,et al.  Central action of 5-HT3 receptor ligands in the regulation of sleep-wakefulness and raphe neuronal activity in the rat , 1992, Neuropharmacology.

[48]  L. Sanford,et al.  A serotonergic (5-HT2) receptor mechanism in the laterodorsal tegmental nucleus participates in regulating the pattern of rapid-eye-movement sleep occurrence in the rat , 2004, Brain Research.

[49]  M. Jouvet.  Neuromédiateurs et facteurs hypnogènes. , 1984 .

[50]  M. Funahashi,et al.  Activation of presynaptic 5-HT3 receptors facilitates glutamatergic synaptic inputs to area postrema neurons in rat brain slices. , 2004, Methods and findings in experimental and clinical pharmacology.

[51]  J. Neumaier,et al.  Quantitative mapping of tryptophan hydroxylase‐2, 5‐HT1A, 5‐HT1B, and serotonin transporter expression across the anteroposterior axis of the rat dorsal and median raphe nuclei , 2006, The Journal of comparative neurology.

[52]  Jonathan D. Morrow,et al.  Effects of serotonergic activation by 5-hydroxytryptophan on sleep and body temperature of C57BL/6J and interleukin-6-deficient mice are dose and time related. , 2008, Sleep.

[53]  R. Silveira,et al.  Depletion of brain serotonin by 5,7-DHT: effects on the 8-OH-DPAT-induced changes of sleep and waking in the rat , 1994, Psychopharmacology.

[54]  R. Vertes,et al.  Efferent and afferent connections of the dorsal and median raphe nuclei in the rat , 2008 .

[55]  E. Bixler,et al.  Buspirone: sedative or stimulant effect? , 1991, The American journal of psychiatry.

[56]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[57]  Dennis McGinty,et al.  Hypothalamic control of sleep. , 2007, Sleep medicine.

[58]  J. Leitao,et al.  Effects of ritanserin on sleep disturbances of dysthymic patients , 2004, Psychopharmacology.

[59]  K. Semba,et al.  Aminergic and cholinergic afferents to REM sleep induction regions of the pontine reticular formation in the rat , 1993, The Journal of comparative neurology.

[60]  D. Monti,et al.  Increased waking after intra-accumbens injection of m-chlorophenylbiguanide: prevention with serotonin or dopamine receptor antagonists. , 1995, European journal of pharmacology.

[61]  J. Palacios,et al.  Localization of 5-HT1B, 5-HT1Dα, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain , 1994, Neuropharmacology.

[62]  J. Barchas,et al.  Serotonin and behavior , 1973 .

[63]  E. Bagdy,et al.  Feedback Stimulation of Somatodendritic Serotonin Release: A 5-HT3 Receptor-Mediated Effect in the Raphe Nuclei of the Rat , 1998, Brain Research Bulletin.

[64]  B. Roth,et al.  Control of Serotonergic Function in Medial Prefrontal Cortex by Serotonin-2A Receptors through a Glutamate-Dependent Mechanism , 2001, The Journal of Neuroscience.

[65]  D. Pal,et al.  GABA in pedunculo pontine tegmentum regulates spontaneous rapid eye movement sleep by acting on GABAA receptors in freely moving rats , 2004, Neuroscience Letters.

[66]  M. Davis,et al.  5-hydroxytryptamine1A-like receptor activation in the bed nucleus of the stria terminalis: electrophysiological and behavioral studies. , 2004, Neuroscience.

[67]  M. Staufenbiel,et al.  Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera , 1995, Neuropharmacology.

[68]  M. Jouvet,et al.  Mapping of cholinoceptive brainstem structures responsible for the generation of paradoxical sleep in the cat. , 1989, Archives italiennes de biologie.

[69]  G. Aghajanian,et al.  Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices , 1983, Brain Research.

[70]  Paul J. Harrison,et al.  The distribution of 5-HT6 receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT6 receptor antagonist [125I]SB-258585 , 2002, Brain Research.

[71]  B. Saletu,et al.  Effects of Selective Serotonin Reuptake Inhibitors on Objective and Subjective Sleep Quality , 2000, Neuropsychobiology.

[72]  R. Jakus,et al.  Increased wakefulness, motor activity and decreased theta activity after blockade of the 5‐HT2B receptor by the subtype‐selective antagonist SB‐215505 , 2004, British journal of pharmacology.

[73]  R. Luthringer,et al.  Nelotanserin, a Novel Selective Human 5-Hydroxytryptamine2A Inverse Agonist for the Treatment of Insomnia , 2010, Journal of Pharmacology and Experimental Therapeutics.

[74]  Carl W. Bazil,et al.  Sleep and epilepsy : the clinical spectrum , 2002 .

[75]  F. Tortella,et al.  Suppressant effects of selective 5-HT2 antagonists on rapid eye movement sleep in rats , 1989, Brain Research.

[76]  J. Monti,et al.  The effects of ritanserin on mood and sleep in abstinent alcoholic patients. , 1993, Sleep.

[77]  R. Eglen,et al.  The pharmacology and distribution of human 5‐hydroxytryptamine2B (5‐HT2b) receptor gene products: comparison with 5‐HT2a and 5‐HT2c receptors , 1995, British journal of pharmacology.

[78]  J. J. Clancy,et al.  Effect of a chronic tryptophan dietary deficiency on the rat's sleep-wake cycle , 1978, Brain Research Bulletin.

[79]  M 100 , 907 , a selective 5-HT antagonist , attenuates dopamine release 2 A in the rat medial prefrontal cortex , .

[80]  C. Kempenaers,et al.  5‐HT2 receptor antagonism and slow‐wave sleep in major depression , 1992 .

[81]  R. Blakely,et al.  Serotonergic dorsal raphe nucleus projections to the cholinergic and noncholinergic neurons of the pedunculopontine tegmental region: a light and electron microscopic anterograde tracing and immunohistochemical study , 1997, The Journal of comparative neurology.

[82]  P. Cowen,et al.  Dose-related effects of selective 5-HT2 receptor antagonists on slow wave sleep in humans , 2005, Psychopharmacology.

[83]  J. Hagan,et al.  5‐HT6 receptor antagonist SB‐271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex , 2004, Synapse.

[84]  C. D. Stern,et al.  Handbook of Chemical Neuroanatomy Methods in Chemical Neuroanatomy. Edited by A. Bjorklund and T. Hokfelt. Elsevier, Amsterdam, 1983. Cloth bound, 548 pp. UK £140. (Volume 1 in the series). , 1986, Neurochemistry International.

[85]  M. Hamon,et al.  Cellular and subcellular localization of 5-hydroxytryptamine1B receptors in the rat central nervous system: immunocytochemical, autoradiographic and lesion studies , 1999, Neuroscience.

[86]  Daniel Hoyer,et al.  Molecular biology of 5-HT receptors , 2008, Behavioural Brain Research.

[87]  B. Bjorvatn,et al.  Sleep and waking following microdialysis perfusion of the selective 5-HT1A receptor antagonist p-MPPI into the dorsal raphe nucleus in the freely moving rat , 2001, Brain Research.

[88]  R. Silveira,et al.  Sleep and waking in 5,7-DHT-lesioned or (−)-pindolol-pretreated rats after administration of buspirone, ipsapirone, or gepirone , 1995, Pharmacology Biochemistry and Behavior.

[89]  D. Popa,et al.  Contribution of 5-HT2 Receptor Subtypes to Sleep–Wakefulness and Respiratory Control, and Functional Adaptations in Knock-Out Mice Lacking 5-HT2A Receptors , 2005, The Journal of Neuroscience.

[90]  D. Monti,et al.  Effects of selective activation of the 5-HT1B receptor with CP-94,253 on sleep and wakefulness in the rat , 1995, Neuropharmacology.

[91]  J. Monti,et al.  Activation of the serotonin 5-HT3 receptor in the dorsal raphe nucleus suppresses REM sleep in the rat , 2008, Progress in Neuro-psychopharmacology and Biological Psychiatry.

[92]  B. Waterhouse,et al.  Glutamatergic afferent projections to the dorsal raphe nucleus of the rat , 2003, Brain Research.

[93]  B. Roth,et al.  Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. , 2008, Expert opinion on pharmacotherapy.

[94]  Stephen R. Morairty,et al.  Selective 5HT2A and 5HT6 receptor antagonists promote sleep in rats. , 2008, Sleep.

[95]  B. Bjorvatn,et al.  Effects of the selective 5‐HT1B agonist, CGS 12066B, on sleep/waking stages and EEG power spectrum in rats , 1994, Journal of sleep research.

[96]  A. Borbély,et al.  Sleep regulation after reduction of brain serotonin: effect of p-chlorophenylalanine combined with sleep deprivation in the rat. , 1982, Sleep.

[97]  M. Davis,et al.  5-hydroxytryptamine1a-likereceptor activation in the bed nucleus of the stria terminalis: Electrophysiological and behavioral studies , 2004, Neuroscience.

[98]  F. Bloom,et al.  Distribution of neurons expressing immunoreactivity for the 5HT3 receptor subtype in the rat brain and spinal cord , 1998, The Journal of comparative neurology.

[99]  M. Jouvet,et al.  The role of monoamines and acetylcholine-containing neurons in the regulation of the sleep-waking cycle. , 1972, Ergebnisse der Physiologie, biologischen Chemie und experimentellen Pharmakologie.

[100]  D. Rainnie,et al.  The response of neurons in the bed nucleus of the stria terminalis to serotonin: Implications for anxiety , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[101]  J. Monti,et al.  Dose‐dependent effects of the 5‐HT1A receptor agonist 8‐OH‐DPAT on sleep and wakefulness in the rat , 1992, Journal of sleep research.

[102]  M. Hamon,et al.  Ultrastructural localization of 5‐hydroxytryptamine1A receptors in the rat brain , 1996, Journal of neuroscience research.

[103]  J. Abrams,et al.  Anatomic and Functional Topography of the Dorsal Raphe Nucleus , 2004, Annals of the New York Academy of Sciences.

[104]  Barry L. Jacobs,et al.  Raphe unit activity in freely moving cats: Correlation with level of behavioral arousal , 1979, Brain Research.

[105]  D. Rainnie,et al.  Microdialysis perfusion of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH- DPAT) in the dorsal raphe nucleus decreases serotonin release and increases rapid eye movement sleep in the freely moving cat , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[106]  W. Dement,et al.  The effects of buspirone on sleep in the rat , 1986, Neuroscience Letters.

[107]  M. I. Smith,et al.  Effect of SB-243213, a selective 5-HT2C receptor antagonist, on the rat sleep profile A comparison to paroxetine , 2002, Pharmacology Biochemistry and Behavior.

[108]  A. Charara,et al.  Chemoarchitecture of the primate dorsal raphe nucleus , 1998, Journal of Chemical Neuroanatomy.

[109]  Contribution of the "knock-out" technology to understanding the role of serotonin in sleep regulations. , 2004, Archives italiennes de biologie.

[110]  A. Sleight,et al.  5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. , 1998, The Journal of pharmacology and experimental therapeutics.

[111]  B. Jacobs,et al.  Structure and function of the brain serotonin system. , 1992, Physiological reviews.

[112]  Floyd E. Bloom,et al.  The Biochemical Basis of Neuropharmacology , 1978 .

[113]  J. Monti,et al.  Differential effects of the 5-HT1A receptor agonist flesinoxan given locally or systemically on REM sleep in the rat. , 2003, European journal of pharmacology.

[114]  Ronald M. Harper,et al.  Dorsal raphe neurons: depression of firing during sleep in cats , 1976, Brain Research.

[115]  B. Roth,et al.  Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders , 2008 .

[116]  Hans-Jürgen Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[117]  R. Wehrle,et al.  Antagonism of serotonergic 5‐HT2A/2C receptors: mutual improvement of sleep, cognition and mood? , 2009, The European journal of neuroscience.

[118]  Effects of Antidepressant Treatment on Sleep EEG in Depression , 1996 .

[119]  B. Jacobs,et al.  Depletion of brain serotonin following intraventricular 5,7-dihydroxytryptamine fails to disrupt sleep in the rat , 1976, Brain Research.

[120]  C. Kempenaers,et al.  5-HT2 receptor antagonism and slow-wave sleep in major depression. , 1992, Acta psychiatrica Scandinavica.

[121]  S. Henriksen,et al.  5-HT7 Receptor Inhibition and Inactivation Induce Antidepressantlike Behavior and Sleep Pattern , 2005, Biological Psychiatry.

[122]  M. Mancia,et al.  5-hydroxytryptophan, but not l-tryptophan, alters sleep and brain temperature in rats , 1999, Neuroscience.

[123]  P. Celada,et al.  The activation of 5‐HT2A receptors in prefrontal cortex enhances dopaminergic activity , 2005, Journal of neurochemistry.

[124]  E. Kidd,et al.  Inhibition of 5-hydroxytryptamine neuronal activity by the 5-HT agonist, DOI. , 1991, European journal of pharmacology.

[125]  S. Crochet,et al.  Differentiation of presumed serotonergic dorsal raphe neurons in relation to behavior and wake–sleep states , 2001, Neuroscience.

[126]  P. Cowen,et al.  Slow wave sleep and 5-HT2 receptor sensitivity in generalised anxiety disorder: a pilot study with ritanserin , 2005, Psychopharmacology.

[127]  J. Monti,et al.  Effects of activation and blockade of 5-HT2A/2C receptors in the dorsal raphe nucleus on sleep and waking in the rat , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[128]  D. Rainnie,et al.  Presynaptic 5-HT1B receptor-mediated serotonergic inhibition of glutamate transmission in the bed nucleus of the stria terminalis , 2010, Neuroscience.

[129]  J. Monti,et al.  A study of the brain structures involved in the acute effects of fluoxetine on REM sleep in the rat. , 2005, The international journal of neuropsychopharmacology.

[130]  R. Andrade,et al.  5-Hydroxytryptamine2 and 5-hydroxytryptamine1A receptors mediate opposing responses on membrane excitability in rat association cortex , 1991, Neuroscience.

[131]  D. Monti,et al.  Increased REM sleep after intra-dorsal raphe nucleus injection of flesinoxan or 8-OHDPAT: prevention with WAY 100635 , 2002, European Neuropsychopharmacology.

[132]  C. Idzikowski,et al.  5-Hydroxytryptamine-2 antagonist increases human slow wave sleep , 1986, Brain Research.

[133]  J. A. Hobson,et al.  A cholinoceptive desynchronized sleep induction zone in the anterodorsal pontine tegmentum: Locus of the sensitive region , 1990, Neuroscience.

[134]  M. Jouvet,et al.  Insomnia following parachlorophenylalanin in the rat , 1968 .

[135]  R. Webster.  Neurotransmitters, Drugs and Brain Function , 2001 .

[136]  B. Jacobs,et al.  Serotonin and sleep : molecular, functional and clinical aspects , 2008 .

[137]  M. Stryker,et al.  Sleep and Sleep Homeostasis in Mice Lacking the 5-HT2c Receptor , 2002, Neuropsychopharmacology.

[138]  M. Opp,et al.  Interleukin‐1 inhibits firing of serotonergic neurons in the dorsal raphe nucleus and enhances GABAergic inhibitory post‐synaptic potentials , 2007, The European journal of neuroscience.

[139]  S. Maier,et al.  Differential expression of 5HT‐1A, α1b adrenergic, CRF‐R1, and CRF‐R2 receptor mRNA in serotonergic, γ‐aminobutyric acidergic, and catecholaminergic cells of the rat dorsal raphe nucleus , 2004 .

[140]  R. Jakus,et al.  Despite Similar Anxiolytic Potential, the 5-Hydroxytryptamine 2C Receptor Antagonist SB-242084 [6-Chloro-5-methyl-1-[2-(2-methylpyrid-3-yloxy)-pyrid-5-yl Carbamoyl] Indoline] and Chlordiazepoxide Produced Differential Effects on Electroencephalogram Power Spectra , 2005, Journal of Pharmacology and Experimental Therapeutics.

[141]  H. McFarlane,et al.  M100,907, a selective 5-HT2A antagonist, attenuates dopamine release in the rat medial prefrontal cortex , 2001, Brain Research.

[142]  E. Jones,et al.  Neurotransmitters in the cerebral cortex. , 1986, Journal of neurosurgery.

[143]  Xiaohong Ma,et al.  Selective 5‐HT1B receptor inhibition of glutamatergic and GABAergic synaptic activity in the rat dorsal and median raphe , 2006, The European journal of neuroscience.

[144]  S. Henriksen,et al.  Sleep changes during chronic administration of parachlorophenylalanine. , 1972, Revue canadienne de biologie.

[145]  Takeshi Kaneko,et al.  Morphological features and electrophysiological properties of serotonergic and non-serotonergic projection neurons in the dorsal raphe nucleus An intracellular recording and labeling study in rat brain slices , 2001, Brain Research.

[146]  C. Lowry,et al.  Topographic organization and chemoarchitecture of the dorsal raphe nucleus and the median raphe nucleus , 2008 .

[147]  S. Sesack,et al.  Prefrontal cortical projections to the rat dorsal raphe nucleus: Ultrastructural features and associations with serotonin and γ‐aminobutyric acid neurons , 2004, The Journal of comparative neurology.

[148]  M. Mariotti,et al.  Interleukin‐1β enhances non‐rapid eye movement sleep when microinjected into the dorsal raphe nucleus and inhibits serotonergic neurons in vitro , 2003, The European journal of neuroscience.

[149]  L. Dawson,et al.  In vivo effects of the 5‐HT6 antagonist SB‐271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5‐HT, glutamate and aspartate , 2000, British journal of pharmacology.

[150]  E. V. Bockstaele,et al.  Topography of serotonin neurons in the dorsal raphe nucleus that send axon collaterals to the rat prefrontal cortex and nucleus accumbens , 1993, Brain Research.

[151]  R. Kirov,et al.  Age-dependent effect of ketanserin on the sleep-waking phases in rats. , 1998, The International journal of neuroscience.

[152]  M. Leopoldo,et al.  The serotonin 5-HT7 receptor agonist LP-44 microinjected into the dorsal raphe nucleus suppresses REM sleep in the rat , 2008, Behavioural Brain Research.

[153]  C. Dugovic,et al.  5-HT2 receptors could be primarily involved in the regulation of slow-wave sleep in the rat. , 1987, European journal of pharmacology.

[154]  R. Hen,et al.  Key Role of 5-HT1B Receptors in the Regulation of Paradoxical Sleep as Evidenced in 5-HT1B Knock-Out Mice , 1999, The Journal of Neuroscience.

[155]  P. Torterolo,et al.  GABAergic mechanisms in the pedunculopontine tegmental nucleus of the cat promote active (REM) sleep , 2002, Brain Research.

[156]  I. Martin,et al.  Molecular biology of 5-HT receptors , 1994, Neuropharmacology.

[157]  G. Aston-Jones,et al.  A 5-hydroxytryptamine2 agonist augments γ-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neurons , 1993, Neuroscience.

[158]  L. Sanford,et al.  Central administration of two 5-HT receptor agonists: Effect on REM sleep initiation and PGO waves , 1994, Pharmacology Biochemistry and Behavior.

[159]  D. Wong,et al.  Localization of 5-HT3 receptors in the rat brain using [3H]LY278584 , 1991, Brain Research.

[160]  H. Steinbusch,et al.  Serotonin-immunoreactive neurons and their projections in the CNS , 1984 .